Health canada authorizes moderna's omicron-targeting bivalent covid-19 booster vaccine

Mrna-1273.214 is the first omicron-targeting bivalent covid-19 booster vaccine approved in canada study results show mrna-1273.214 has demonstrated significantly higher antibody titers against omicron ba.1 and ba.4/5 subvariants when compared with mrna-1273 approval follows agreement with the government of canada to supply 12 million doses of omicron-targeting bivalent covid-19 boosters cambridge, ma / accesswire / september 1, 2022 / moderna, inc . (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that health canada has authorized the use of its omicron-targeting bivalent covid-19 booster vaccine, mrna-1273.214 (spikevax bivalent original/omicron) as a booster dose for active immunization against covid-19 caused by the sars-cov-2 virus in individuals 18 years of age and older.
MRNA Ratings Summary
MRNA Quant Ranking